Esperion appoints Craig Thompson to Board of Directors; board now has eight members

Esperion Therapeutics, Inc.

Craig Thompson appointed to Esperion Board as independent Class II director, effective July 1, 2025.
Board expands from seven to eight members; Thompson will serve on Compliance, Nominating/Gov., and Commercial Committees.
Thompson is CEO of Cerevance and has held leadership roles at Neurana, Anthera, Tetraphase, Trius, Pfizer, and Merck.
He led commercial development of torcetrapib/atorvastatin at Pfizer and was involved in Trius' $700M+ acquisition by Cubist.
Thompson holds a BComm from McMaster University and an MBA from the University of Notre Dame.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.